Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

American Journal of Pathology

Volumn 161, Issue 5, 2002, Pages 1917-1924

  Hu, Limin ^a   Hofmann, Judith ^a   Zaloudek, Charles ^b   Ferrara, Napoleone ^c   Hamilton, Thomas ^d   Jaffe, Robert B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PACLITAXEL; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER INHIBITION; CELL LINE; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0036840759     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64467-7     Document Type: Article

References (46)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 1993, 329:1550-1559
2. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R, Feder J: Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989, 264:20017-20024
3. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM, Dvorak HF: Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995, 55:360-368
4. Barton DP, Cai A, Wendt K, Young M, Gamero A, DeCesare S: Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997, 3:1579-1586
5. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marme D, Gastl G: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999, 85:178-187
6. Mesiano S, Ferrara N, Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 1998, 153:1249-1256
7. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ: Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000, 16:445-454
8. Hu L, Huang Z, Ferrara N, Jaffe RB: Reversal of pre-existing ovarian carcinoma-associated ascites with a human monoclonal antibody to vascular endothelial growth factor. Abstracts, 81st Annual Meeting Endocrine Society, San Diego, CA, June 12-15, 1999
9. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG: Paclitaxel: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992, 19:646-662
10. Cain JM, Collins C, Petersdorf S, Figge DC, Tamimi HK, Greer BE, Livingston RB: Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. Am J Obstet Gynecol 1996, 1746:1688-1694
11. Williams S, Blessing JA, Liao SY, Ball H, Hanjani P: Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group. J Clin Oncol 1994, 12: 701-706
12. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of paclitaxel, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83:1797-1805
13. Eisenhauer EA, Vermorken JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998, 55:5-30
14. Sorger PK, Dobles M, Tournebize R, Hyman AA: Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 1997, 9:807-814
15. Slichenmyer WJ, Von Hoff DD: New natural products in cancer chemotherapy. J Clin Pharmacol 1990, 30:770-788
16. Manthey CL, Brandes ME, Perera PY, Vogel SN: Paclitaxel increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J Immunol 1992, 149:2459-2465
17. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, Peters LJ: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with paclitaxel. Cancer Chemother Pharmacol 1995, 35:297-303
18. Danesi R, Figg WD, Reed E, Myers CE: Paclitaxel (Taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 1995, 47:1106-1111
19. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma Clin Cancer Res 2000, 6:4874-4884
20. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R, Dinney CP: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 2000, 6:2635-2643
21. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 1993, 362:841-844
22. Kubota T, Matsuzaki SW, Hoshiya Y, Watanabe M, Kitajima M, Asanuma F, Yamada Y, Koh JI: Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol 1997, 64:115-121
23. Nicoletti MI, Lucchini V, Massazza G, Abbott BJ, D'Incalci M, Giavazzi R: Antitumor activity of paclitaxel (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Ann Oncol 1993, 4:151-155
24. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ: Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998, 90:447-454
25. Teicher BA, Holden SA, Ara G, Dupuis NP, Liu F, Yuan J, Ikebe M, Kakeji Y: Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy. Int J Cancer 1995, 61:732-737
26. Satoh H, Ishikawa H, Fujimoto M, Fujiwara M, Yamashita YT, Yazawa T, Ohtsuka M, Hasegawa S, Kamma H: Combined effects of TNP-470 and paclitaxel in human non-small cell lung cancer cell lines. Anticancer Res 1998, 18:1027-1030
27. Placidi L, Scott EC, Eckoff D, Bynon S, Sommadossi JP: Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes. Drug Metab Dispos 1999, 27:623-626
28. Shishido T, Yasoshima T, Denno R, Mukaiya M, Sato N, Hirata K: Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res 1998, 89:963-969
29. Klement G. Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105:R15-R24
30. Bao R, Connolly DC, Murphy M, Green J, Weinstein J, Pisarcik DA, Hamilton TC: Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2000, 294:522-528
31. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002, 99:4349-4354
32. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002, 62:1087-1092
33. Hu YL. Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, Jaffe RB: Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Jnst 2001, 93:762-768
34. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT: Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999, 14:31-36
35. Luo JC, Toyoda M, Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody Cancer Res 1998, 58:2594-2600
36. Shibuya M, Luo JC, Toyoda M, Yamaguchi S: Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother Pharmacol 1999, 43:S72-S77
37. Luo JC, Toyoda M, Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody, Cancer Res 1998, 58:2594-2600
38. Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM: Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation. Oncologist 2000, 1:S45-S50
39. Xu L, Xie K, Mukaida N, Matsushima K, Fidler IJ: Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res 1999, 59:5822-5829
40. Kitadai Y, Takahashi Y, Haruma K, Naka K, Sumii K, Yokozaki H, Yasui W, Mukaida N, Ohmoto Y, Kajiyama G, Fidler IJ, Tahara E: Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer 1999, 81:647-653
41. Singh RK, Gutman M, Radinsky R. Bucana CD, Fidler IJ: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994. 54:3242-3247
42. Lee F, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP: IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 2000, 164:2769-2775
43. Costa A, Villa R, Zaffaroni N, Santi S, Bearzatto A, Silvestrini R: Pactitaxel induces apoptosis in various cancer cell lines: Comparison among different methodological approaches. Eur J Histochem 1997, 2:69-70
44. Al-alami O, Sammons J, Martin JH, Hassan HT: Divergent effect of paclitaxel on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U937 CD34 negative human leukaemia cells. Leuk Res 1998, 22:939-945
45. Frankel A, Buckman R, Kerbel RS: Abrogation of paclitaxel-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997, 57:2388-2393
46. Sandoval D, Gukovskaya A, Reavey P, Gukovsky S, Sisk A, Braquet P: The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology 1996, 4:1081-1091